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Abstract
Introduction Frequency-dependent acceleration of relaxation
(FDAR) ensures appropriate ventricular filling at high heart rates
and results from accelerated sarcoplasmic/endoplasmic
reticulum calcium ATPase (SERCA) activity independent of
calcium removal from the cell. Because lipopolysaccharide
(LPS) challenge may induce aberrations in calcium trafficking
and protein phosphorylation, we tested whether LPS would
abolish FDAR in rats.
Methods Following LPS injection, changes in force-frequency
relationship and FDAR were studied in cardiomyocytes, isolated
hearts and in vivo by echocardiography. Calcium uptake and
phosphatase activities were studied in sarcoplasmic reticulum
(SR) vesicle preparations. Western blots of phospholamban
and calcium/calmodulin-dependent protein kinase II, and serine/
threonine phosphatase activity were studied in heart
preparations.
Results In cardiomyocytes and isolated heart preparations,
reductions in time constant of relaxation (τ) and time to 50%
relaxation at increasing rate of pacing were blunted in LPS-
treated rats compared with controls. Early diastolic velocity of
the mitral annulus (Ea), a relaxation parameter which correlates
in vivo with τ, was reduced in LPS rats compared with control
rats. LPS impaired SR calcium uptake, reduced phospholamban
phosphorylation and increased serine/threonine protein
phosphatase activity. In vivo inhibition of phosphatase activity
partially restored FDAR, reduced phosphatase activity and
prevented phospholamban dephosphorylation in LPS rat hearts.
Conclusions LPS impaired phospholamban phosphorylation,
cardiac force-frequency relationship and FDAR. Disruption of
frequency-dependent acceleration of LV relaxation, which
normally participates in optimal heart cavity filling, may be
detrimental in sepsis, which is typically associated with elevated
heart rates and preload dependency.
Introduction
Apart from the Frank-Starling mechanism, force-frequency
relationship represents a major intrinsic regulatory factor that
is essential for the immediate adjustment of cardiac contractile
function to rapid changing requirements of blood supply. The
frequency-dependent gain in contractility is an intrinsic prop-
erty of cardiac muscle present in all mammals and allows for
greater contractile force [1]. Not only does the heart generally
beat stronger when it is stimulated to contract faster, the
kinetic of contraction is also accelerated, that is, the fre-
quency-dependent acceleration of relaxation (FDAR) [1,2].
From a physiological perspective, FDAR participates in the
maintenance of efficient ventricular filling and coronary blood
at higher heart rates, despite a decreased diastolic time inter-
val [2]. In clinical sepsis, left ventricle (LV) systolic dysfunction
and altered diastolic relaxation are typically observed [3]. In
contrast, only a limited number of studies have evaluated the
frequency-dependent gain in contractility in the septic myocar-
dium. In these studies, inotropic responsiveness to changes in
frequency of stimulation from lipopolysaccharide (LPS)
ANOVA: analysis of variance; CaMKII: calcium/calmodulin protein kinase type II; dP/dtmax: LV developed pressure first maximal positive derivatives; 
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treated hearts was significantly less than controls [4,5].
Effects of LPS on FDAR have not been previously described.
Force-frequency relationship and FDAR are primarily related to
changes in intracellular calcium transients [1,2]. The exact
molecular basis for FDAR has not been resolved, yet an attrac-
tive mechanism implicates thr-17 phosphorylation of phos-
pholamban by calcium/calmodulin protein kinase II (CaMKII)
[6-8]. In addition to these intrinsic heart regulatory processes,
stimulation of β-adrenoceptors increases contractility and
accelerates relaxation through accumulation of cyclic AMP
and subsequent activation of protein kinase A. Activated pro-
tein kinase A phosphorylates phospholamban at ser-16 resi-
due that relieves sarcoplasmic/endoplasmic reticulum calcium
ATPase (SERCA) inhibition, enhances removal of calcium
from the cytosol and increased heart contractility [8]. Con-
versely, activation of protein phosphatase-1 and 2, which are
the major phosphatases functionally relevant in the heart,
dephosphorylate phospholamban and favour SERCA inhibi-
tion [8].
We hypothesised that intracellular calcium traffic aberrations
and changes in calcium handling protein phosphorylation
reported in LPS challenge [9-11] would alter FDAR response.
For example, reduced phospholamban phosphorylation by
protein kinase inhibition [10,12] and activation of protein
phosphatases that dephosphorylate phospholamban [13,14]
typically observed in sepsis may in turn alter inotropic and
relaxation responsiveness with changes in frequency of heart
stimulation.
The present experiment was undertaken to assess the poten-
tial effects of LPS on force-frequency relationship and FDAR
in rats. Preparations of intact cardiomyocytes, isolated hearts
and echocardiography were evaluated. First, we tested
whether LPS would reduce phospholamban phosphorylation
and disrupt cardiac force-frequency relationship and FDAR.
As FDAR was disrupted in LPS-treated rats, we next tested
whether phospholamban dephosphorylation induced by LPS
was associated with CaMKII activation (which phosphorylates
phospholamban at the thr-17 residue) and serine/threonine




All work was performed under a protocol approved by the Uni-
versity of Lille's Institutional Animal Care and Research Advi-
sory Committee. The investigation conforms with the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health. Under brief isoflurane anaesthe-
sia, adult male Sprague-Dawley rats (weighing 250 to 300 g)
(Charles River Lab, L'Arbresle, France) were treated with
either 10 mg/kg of LPS from Escherichia coli serotype
055:B5 in 500 μL saline or 500 μL saline administered intra-
venously via the dorsal penile vein. Where indicated, we used
tacrolimus (FK506; Fujisawa, La Celle St Cloud, France) as a
protein phosphatase type 2 inhibitor. Tacrolimus-treated LPS-
challenged rats received 0.01 mg/kg of tacrolimus in 500 μL
LPS in saline mixture. Four hours after treatments, rats were
prepared for echocardiography, and isolated heart or single
cardiac myocyte evaluations.
Left ventricular cardiomyocyte shortening
Ventricular myocytes were isolated as previously described
[15]. For contraction amplitude, cells were placed in a flow
chamber and field-stimulated with pulses of 5 ms duration at a
frequency of 0.5 and 2 Hz. As an index of acceleration of relax-
ation, we calculated time constant of relaxation (tau, τ) at 0.5
Hz and 2 Hz.
Myocardial in isolated heart preparation
Myocardial contractile function was studied using a modified
Langendorff isolated heart preparation technique, as previ-
ously described [16]. After the equilibration period, heart
parameters were recorded at 150 and 300 beats/minute pac-
ing rates. Left ventricular developed pressure (LVDP), its first
maximal derivatives (dP/dtmax (positive) and dP/dtmin (nega-
tive)) and coronary perfusion pressure were recorded using a
Biopac Data Acquisition System (Biopac Systems Inc.,
Goleta, CA, USA). Half-relaxation time (t1/2) and time constant
of LV isovolumic relaxation (tau, τ) were calculated at 150 and
300 beats/minute. LV pressure from the time of peak negative
dP/dt to 5 mmHg above LV end diastolic pressure was fitted
by the monoexponential equation:
p(t) = pe-t/τ
where t is time obtained, e is natural logarithm and p is pres-
sure [17]. Time constant of LV isovolumic relaxation (τ) were
calculated from the above equation.
Echocardiography evaluation
Rat echocardiography was performed as previously described
[18] at baseline and four hours after intravenous administra-
tion of LPS in the same individual. Two-dimensional (2D) Dop-
pler echocardiography was obtained in the left lateral
decubitus position with a linear transducer (14 MHz, Acuson
Sequoia C512 system, Mountain View, CA, USA). All
echocardiographs and data analysis were performed by MS,
blinded for group design. Measurements were performed after
magnification to ensure optimal visualisation of cardiac cham-
bers, and depth was set at 20 mm. Gain was set for best imag-
ing and compression was 65 dB. For the assessment of LV
function, parasternal short and long axis 2D views were sam-
pled to obtain at least 15 images per second. For blood flow
and tissue Doppler measurements, the sweep speed was 200
mm/s.Available online http://ccforum.com/content/13/1/R14
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The anterior chest hair was shaved off and recordings were
made under continuous monitoring by fixing the electrodes to
the limbs. At least three cardiac cycles were used for each
measurement, and the average value was taken. M-mode trac-
ing of the LV was obtained from the parasternal long axis view
allowing the measurement of LV end diastolic diameter, LV
end systolic diameter, and diastolic posterior and septal wall
thickness in accordance with the American Society of
Echocardiography guidelines. The following parameters were
calculated: left ventricular weight = 1.04 × (LVEDD + PW +
SW), and fractional shortening = (LVEDD - LVESD)/LVEDD,
where LVEDD is left ventricle end diastolic diameter, LVESD
is left ventricle end systolic diameter, PW is diastolic posterior
wall thickness and SW is septal wall thickness.
From the parasternal short axis view, pulmonary flow was
recorded using pulsed Doppler with the smallest sample vol-
ume placed at the level of the pulmonary annulus. Cardiac out-
put was calculated as the product of the pulmonary forward
stroke volume:
VTI × D2/4 × π
where D is the diameter of the right ventricle outflow tract, and
heart rate, and VTI is velocity time integral. Pulsed Doppler
mitral inflow velocities were obtained by placing a 0.6 mm
sample volume between the tips of the mitral leaflets in the api-
cal four-chamber view. The Doppler beam was aligned parallel
to the direction of flow. Isovolumic relaxation time was meas-
ured as the interval between aortic closure and the start of
mitral flow. Ea was obtained from the four apical chamber view
using tissue Doppler imaging as an indice of LV relaxation.
Data were stored on compact discs in DICOM format and
measured offline with the Echo PAC PC Software release 08
(General Electrics, Horten, Norway). Transthoracic echocardi-
ography was performed under inhaled sevoflurane anaesthe-
sia, 100% oxygen and spontaneous respiration. Increases in
sevoflurane concentrations (2 to 4%) were used to decrease
heart rate by about 20%. An echo image is shown in Figure 1.
Western blot analysis
Ventricular heart tissue was homogenised with a Polytron
homogeniser (Glen Mills Inc., Clifton, NJ., USA). Protein
extracts from heart tissue (50 μg) were separated by a 4 to
12% bis-Tris HCl-buffered polyacrylamide gel (Invitrogen,
Carlsbad, CA, USA) and subjected to Western blotting for
SERCA2a, phospholamban, thr17-phospho-phospholamban,
CAMKII and phospho-CAMKII antibodies (Affinity Biorea-
gents, Golden, CO, USA). Bound antibodies were detected
by the use of enhanced chemiluminescence's Plus kit (Amer-
sham, Freiburg, Germany).
SR vesicle calcium uptake
Sarcoplasmic reticulum (SR) microsomes were obtained from
rat ventricles following ultracentrifugation (100,000 g) proce-
dures [19]. The whole procedure was carried out in a cold
room, at 4°C and in the presence of protease inhibitors (0.1
μM aprotinin, 500 μM benzamidine, 1 μM leupeptine, 1 μM
pepstatin A 200 μM and phenylmethylsulphonyl fluoride). SR
preparation was placed in a Teflon chamber equipped with a
calcium-selective microelectrode (WPI, Aston, UK) to assess
calcium-uptake activity. Changes of medium (ie, extramicro-
somal) calcium concentration were recorded continuously. At
the end of the preincubation period, the reaction was initiated
by addition of 1.5 mmol ATP after which calcium chloride
pulse was added. Calcium is then rapidly taken up by the SR
vesicles, resulting in a return of extramicrosomal calcium con-
centration to baseline levels. At the end of the experiments,
thapsigargin was added to block SR calcium uptake.
SR phosphatase activity assay
SR protein phosphatase activity was assessed in SR vesicles
of rat with the Protein Serine/Threonine Phosphatase Assay
System (Millipore; Bioscience, St Quentin en Yvelines,
France) according to the manufacturer's instructions [20].
Statistical analysis
Results were analysed with the SPSS for Windows software,
version 11.0.1 (SPSS France, Paris, France). Data represent
Figure 1
Representative spectral recording of blood flow Doppler and tissue  Doppler imaging recorded at the spectral mitral annulus Representative spectral recording of blood flow Doppler and tissue 
Doppler imaging recorded at the spectral mitral annulus. (a) The blood 
flow Doppler was recorded at the tips of the mitral leaflets and (b) tis-
sue Doppler imaging was recorded at the spectral mitral annulus in a 
normal rat at heart rate of 350 beats/minute and 250 beats/minute. 
Note that in the presence of minimal changes in early flow and late flow 
mitral diastolic wave velocities, early diastolic mitral annulus velocity is 
lower when heart rate is decreased.Critical Care    Vol 13 No 1    Joulin et al.
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means ± standard error of the mean. Statistical nonparametric
Mann-Whitney test was used to compare unmatched groups
(controls and LPS-treated rats). Statistical comparisons
between means were made by two-way analysis of variance
(ANOVA) for repeated measurements on frequency effect
(main effects; two levels and treatment effect; two levels), and
the interactive effects. Post hoc analyses were made using
Dunnett's test comparing the variable group with the control
group. Statistical significance was assigned to p < 0.05.
Results
Single cardiomyocyte and myocardial function
Shortening of single cardiomyocytes isolated from LPS-chal-
lenged rats was reduced compared with controls. Isolated
heart-derived contractility and relaxation parameters, such as
LVDP and its first maximal derivatives, were also reduced in
LPS-challenged rats (Table 1). Echocardiography evaluation
shows that LPS challenge induced about a 15% decrease in
LV ejection fraction and about a 35% decrease in fractional
shortening, compared with controls (Table 1). Decreases in
indexes of cardiac performance were accompanied by about
a 40% decrease in cardiac output. Ea was reduced in LPS-
challenged rats compared with controls, suggesting perturba-
tions of LV relaxation. Early flow (E)/Ea did not change signifi-
cantly, suggesting minor modification in LV end diastolic
pressure (Table 1). Overall, our results suggested that LPS
induced some degree of hypovolaemia which was associated
with LV diastolic dysfunction.
Force-frequency relationship and frequency-dependent 
acceleration of relaxation
In control cardiomyocytes, increasing rate of pacing from 0.5
to 2 Hz resulted in a positive cell shortening-frequency
response, which was inverted in cardiomyocytes isolated from
LPS-treated rats (Figure 2a). In contrast, similar positive force-
frequency responses were observed in whole heart prepara-
tions, that is, isolated heart and echocardiography, from con-
trol and LPS-treated rats (Figures 2b,c). Overall, LPS resulted
in significantly different force-frequency dependence in cardi-
omyocytes, but not in isolated hearts or in vivo.
In cardiomyocyte and isolated heart preparations, reductions
in time constant of relaxation (τ) (Figures 3a,b) and time to
50% relaxation (data not shown) at increasing rate of pacing
were lower in LPS-treated rats compared with controls.
Echocardiography evaluation at increasing heart rate shown
that ratio of Ea change to heart rate change was reduced in
LPS-treated rats compared with control rats (0.054 ± 0.026
versus 0.035 ± 0.021 cm/sec/beat, n = 5 rats; p < 0.05).
Overall, LPS resulted in significantly different acceleration of





Cardiomyocyte shortening 6.3 ± 0.4% 4.5 ± 0.4%*
LV developed pressure (mmHg) 90 ± 5 65 ± 7*
dP/dtmax (mmHg/second) 2750 ± 100 1650 ± 175*
dP/dtmin (mmHg/second) 1300 ± 215 800 ± 115*
Heart rate (beats/second) 379 ± 13 350 ± 21
LV ejection fraction (%) 62 ± 3 51 ± 8*
LV fractional shortening (%) 46 ± 4 29 ± 6*
Cardiac output (mL/minute) 110 ± 14 65 ± 20*
Transmitral E velocity (cm/second) 87 ± 13 61 ± 5*
Transmitral A velocity (cm/second) 68 ± 21 47 ± 11*
Early diastolic velocity Ea, (cm/second) 8.5 ± 0.9 5.3 ± 1.3*
E/Ea 10.1 ± 2.6 11.5 ± 2.7
Shortening was measured in single cardiomyocytes (20 cells per cell isolation, 6 rats per group). Left ventricle (LV) developed pressure and its 
first derivatives were measured in isolated heart preparations (8 rats per group). Heart rate, LV ejection fraction, LV fractional shortening, cardiac 
output, transmitral and early diastolic velocities were assessed during transthoracic echocardiography (5 rats per group). Results are expressed 
as means ± standard error of the mean and analysed by the mean of unpaired t test. * indicates p < 0.05 vs controls. A = late flow; dP/dtmax = LV 
developed pressure first maximal positive derivatives; dP/dtmin = LV developed pressure first maximal negative derivatives; E = early flow; Ea = 
early diastolic mitral annulus velocity; LPS = lipopolysaccharide.Available online http://ccforum.com/content/13/1/R14
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Heart calcium regulatory proteins expression, SR 
phosphatase activity and SR calcium uptake
LPS treatment was associated with reduction in SR thr17-
phosphorylated phospholamban with no changes in total
phospholamban protein expression (Figure 4). Compared with
controls, LPS challenge did not alter CaMKII activation, that is,
phospho-CaMKII to CaMKII ratio (Figure 4). Total protein
phosphatase activities were higher in SR vesicles isolated
from LPS-treated rats compared with controls rats (Figure 5).
Differential phosphatase activities were evaluated by a range
of doses of okadaic acid (nM), which inhibits all but PP1 and
PP2b phosphatases, and a range of doses of okadaic acid
(μM), which inhibits PP1 phosphatases. Incubation of SR sam-
ples isolated from LPS-treated rats with okadaic acid at 10 nM
had no effects, whereas 1 μM okadaic acid partially reduced
Figure 2
Effects of heart rate changes on contractile performance Effects of heart rate changes on contractile performance. This was 
measured in (a) single cardiomyocytes (n = 6 per group), (b) isolated 
heart (n = 8 per group) and (c) echocardiography (n = 5 per group) 
studies. Results are mean ± standard error of the mean; analysis of var-
iance for repeated measurements on frequency effect, treatment group 
effect and the interactive effects. * p < 0.05 between control and 
lipopolysaccharide (LPS) at each frequency † p < 0.05 between 
groups across frequency. Overall, LPS resulted in significant different 
force-frequency dependence in cardiomyocytes, but not in isolated 
hearts and echocardiography.
Figure 3
Effects of heart rate changes on frequency-dependent acceleration of  relaxation Effects of heart rate changes on frequency-dependent acceleration of 
relaxation. This was measured in (a) single cardiomyocytes (n = 6 per 
group) and (b) isolated heart (n = 8 per group) studies. Results are 
mean ± standard error of the mean; analysis of variance for repeated 
measurements on frequency effect, treatment group effect and the 
interactive effects. * p < 0.05 between control and lipopolysaccharide 
(LPS) at each frequency; † p < 0.05 between groups across frequency. 
Overall, LPS resulted in significant different force-frequency depend-
ence in cardiomyocytes and isolated hearts.Critical Care    Vol 13 No 1    Joulin et al.
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phosphatase activity, suggesting that increases in phos-
phatase activity were only partially related to PP1 and PP2a
activities (Figure 5a). Rate of calcium uptake of SR vesicles
isolated from LPS-treated rats was reduced compared with
controls rats, whereas in vitro incubation with 1 μM okadaic
acid slightly increased the rate of calcium uptake of SR vesi-
cles isolated from LPS-treated rats (Figure 5b).
Effects of phosphatase inhibition on FDAR and 
phospholamban phosphorylation
To evaluate the effects of phosphatase inhibition on FDAR, we
evaluated isolated heart characteristics in a new series of
experiments in control and LPS rats treated with tacrolimus, a
PP2b inhibitor. Tacrolimus in control rats had no effect on LV
contractile function, heart phosphatase activities and phos-
pholamban phosphorylation (data not shown). Compared with
LPS-treated hearts, tacrolimus did not alter LV contractile per-
formance (dP/dtmax: 1650 ± 175 mmHg/second in LPS ver-
sus 1850 ± 200 mmHg/second in LPS-tacrolimus-treated
rats; n = 8 in each group, p > 0.05). Tacrolimus partially
restored FDAR (Figure 6a) and normalised heart phosphatase
activities and phospholamban phosphorylation (Figures 6b,c)
in LPS-treated rats.
Discussion
Consistent with previous studies [21], our results demon-
strated that injection of LPS depresses single cardiomyocyte
and LV contractile performance. For the first time, we have
demonstrated that LPS-induced intrinsic myocardial dysfunc-
tion was frequency dependent with disruption of acceleration
of LV relaxation at increasing heart rate. Loss of this fundamen-
tal adaptive mechanism that ensures optimal LV filling was
accompanied by reduced SR calcium uptake, dephosphoryla-
tion of phospholamban and serine/threonine phosphatase
activity increases.
In LPS-challenged rats, systolic contractile dysfunction was
characterised in single cardiomyocytes, isolated hearts and in
vivo  by echocardiography evaluation. Impairment of heart
relaxation associated with LPS was also observed in isolated
Figure 4
Effects of LPS administration on protein expression in heart tissues Effects of LPS administration on protein expression in heart tissues. Representative Western blots (upper panel) and statistical analysis (bottom pan-
els) of calsequestrin (CSQ), phosphorylated calcium/calmodulin kinase II (P-CaMKII) and total calcium/calmodulin kinase II (CAMKII), thr17-phos-
pho-phospholamban (P-PLP) and total phospholamban (PLP). Results are presented as mean ± standard error of the mean (n = 6 per group). * p < 
0.05 versus controls.Available online http://ccforum.com/content/13/1/R14
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hearts and in vivo preparations. Echocardiography studies fur-
ther documented relaxation abnormalities as reduction of Ea,
a load-independent index of LV relaxation which is impaired in
septic patients [22]. Ea reductions in LPS-treated rats were
observed in the absence of E/Ea changes; suggesting only
minor modification in end-diastolic pressure. The typical posi-
tive force-frequency relationship was replaced by an inverted
relationship in cardiomyocytes isolated from LPS-treated rat
hearts. In contrast, LPS did not alter force-frequency relation-
ships in whole preparations, such as isolated heart and
echocardiography, although contractile performance was
reduced. FDAR was observed in single cardiomyocytes, iso-
lated hearts and in vivo in control rats, whereas LPS blunted
this adaptive phenomenon. Because calcium uptake by the SR
plays a dominant role in clearance of free cytosolic calcium
and thus kinetics of relaxation [6,23], we evaluated calcium
handling in SR preparations isolated from controls and LPS-
treated rats. We found that SERCA-dependent calcium
uptake was reduced in SR preparations of LPS rats, which
was associated with reduced phospholamban th-17 phospho-
rylation and increased serine/threonine protein phosphatase
activities. Phospholamban th-17 phosphorylation was specifi-
cally studied because increasing heart rates mainly implicate
phospholamban phosphorylation at the thr-17 site [6,23].
CaMKII activation, that is the phospho-CaMK to CaMK ratio,
was virtually unchanged in the hearts of LPS-treated rat com-
pared with controls. Hence, we speculated that phospholam-
ban dephosphorylation and reduced SR calcium uptake were
related to increased phosphatase activity rather than reduction
in CaMKII activation. This contention was further supported by
the results that in vitro SR incubation with okadaic acid, a
phosphatase inhibitor, partially restored calcium uptake of SR
isolated from LPS-treated rat hearts.
Next, we tested whether phosphatase inhibition in vivo would
prevent phospholamban dephosphorylation and FDAR pertur-
bations. Okadaic acid, a serine/threonine PP1/PP2a phos-
phatase inhibitor widely used in vitro [24,25], induces
hypotension and death in vivo [26]. Alternatively, non-specific
phosphatase inhibition may be achieved by the use of the cal-
cineurin inhibitor tacrolimus [25]. Because we have previously
reported that immunosuppressive doses of tacrolimus (1 mg/
kg) have deleterious effects on myocardial function in LPS
sepsis [27], low tacrolimus doses were used in this study. We
found that 0.01 mg/kg tacrolimus had minimal effects on LV
systolic performance and partially restored FDAR responsive-
ness in LPS-treated rats. Interestingly, tacrolimus normalised
heart phosphatase activities and phospholamban phosphor-
ylation in LPS-treated rats. These results are consistent with
studies showing that calcineurin inhibition stimulates phos-
pholamban phosphorylation and normalises heart blunted β-
adrenoceptor responsiveness, cardiomyocyte time constant of
relaxation and rate of calcium decrease in spontaneously
hypertensive rats [28].
Our study has important limitations. Our experimental condi-
tions can be considered far removed from the in vivo situation,
that is, use of an experimental LPS model of sepsis and at fre-
quencies well below the in vivo spectrum of the species stud-
ied. This can be particularly true in our cardiomyocyte studies,
in which pacing rates were 0.5 to 2 Hz. Although rates of pac-
Figure 5
Effects of lipopolysaccharide (LPS) administration on sarcoplasmic  reticulum (SR) protein phosphatase activity and SR calcium uptake Effects of lipopolysaccharide (LPS) administration on sarcoplasmic 
reticulum (SR) protein phosphatase activity and SR calcium uptake. 
Okadaic acid (OA) was used in vitro to evaluate differential phos-
phatase activity. First, heart SR vesicles of sham and LPS-treated rats 
were prepared. Then, SR vesicles were incubated with OA in order to 
study phosphatase activity and calcium uptake. Results are presented 
as mean ± standard error of the mean (n = 6 per group). * p < 0.05 ver-
sus controls; # p < 0.05 versus LPS.Critical Care    Vol 13 No 1    Joulin et al.
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ing were standardised in cardiomyocytes and isolated hearts,
heart frequency changes during echocardiography were
achieved by increasing doses of volatile anaesthetics, which
may alter calcium cycling and myocardial function [29]. For
example, halogenated anaesthetics inhibit the post-rest
increase of contractile force by impairing the function of SR.
Moreover, halothane, which activates the calcium-release
channel, can restore the positive shape of the force-frequency
relationship in human myocardium, whereas isoflurane and
sevoflurane did not change the force-frequency relationship
[29]. Hence, volatile (sevoflurane) anaesthesia concentration
that was used to lower heart rate, would also impact on systo-
lic and diastolic function in vivo. In the present study, immedi-
ate effects of heart rate increases on calcium handling were
not evaluated. Instead, we tested whether pre-existing calcium
handling perturbations induced by LPS would have altered
FDAR. Hence, systolic and diastolic changes observed at
increased heart rates could be due to pre-existing calcium
cycling aberrations and abnormal calcium cycling responses
to heart rate increases. We studied calcium handling exclu-
sively in SR preparations, which may not reflect cardiac Ca2+
trafficking. In addition to reduced phospholamban th-17 phos-
phorylation and increased phosphatase activity, sepsis could
also alter FDAR through multiple mechanisms, such as altered
beta-adrenergic signalling and cAMP-dependent kinase activ-
ity, myofibrillar dysfunction and disturbed nitric oxide signal-
ling. Eventually, tacrolimus, which was used to inhibit protein
phosphatase activity, has complex and numerous effects on
the regulation of calcium cycling in the heart through its bind-
ing to its cellular target, the tacrolimus binding proteins.
Figure 6
Effects of calcineurin inhibition by tacrolimus (0.01 mg/kg) Effects of calcineurin inhibition by tacrolimus (0.01 mg/kg). This was measured in hearts isolated from lipopolysaccharide (LPS)-treated rats on (a) 
time constant of LV relaxation (τ), (b) heart protein phosphatase activity and (c) phospho-phospholamban to total phospholamban ratio. Results are 
presented as mean ± standard error of the mean (n = 8 per group). * p < 0.05 versus controls; # p < 0.05 versus LPS.Available online http://ccforum.com/content/13/1/R14
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Conclusions
LPS sepsis impairs LV diastolic function and disrupts LV
FDAR. Mechanisms involved in these alterations included
reduced SR calcium uptake capacities, which may be related
to dephosphorylation of phospholamban and protein phos-
phatase activity increases. We speculated that disruption of
LV FDAR, which normally participates in adequate heart cavity
filling, may be particularly detrimental in sepsis, a pathological
condition typically associated with elevated heart rates and
preload dependency.
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